Lixisenatide vs Cotadutide
Head-to-head comparison of Lixisenatide (Exendin-4-derived GLP-1 receptor agonist) and Cotadutide (MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Lixisenatide | Cotadutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Exendin-4-derived GLP-1 receptor agonist | MEDI0382, long-acting GLP-1 and glucagon receptor dual agonist |
| Molecular Weight | 4858 Da | ~4,700 Da |
| Half-Life | 2-4 hours | Approximately 24 hours |
| Amino Acids | 44 | 37 |
| Typical Dose | 10-20 mcg daily | 0.3-3 mg daily in clinical studies |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 400 | 18 |
| Research Status | Approved | Clinical |
Lixisenatide Benefits
- ✓postprandial glucose control
- ✓modest weight loss
- ✓appetite reduction
- ✓short-acting option
Cotadutide Benefits
- ✓body-weight reduction
- ✓improved insulin sensitivity
- ✓reduced hepatic fat
- ✓appetite suppression
Lixisenatide Dosing
10 mcg SC daily for 14 days|Increase to 20 mcg daily|Inject before the first meal of the day
Cotadutide Dosing
Once-daily SC in trials|Start low and titrate based on tolerance|Monitor GI adverse effects
Lixisenatide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠hypoglycemia when combined with insulin
Cotadutide Side Effects
- ⚠nausea
- ⚠vomiting
- ⚠diarrhea
Research Overview
Lixisenatide
Lixisenatide produces small but measurable weight loss in diabetes trials while improving postprandial glucose excursions. Its shorter half-life makes it a useful reference compound for first-generation incretin mimetics.
Cotadutide
Phase 2 studies reported dose-dependent weight loss and favorable changes in glycemic and liver-related markers. It is one of the most cited synthetic dual-agonist peptides for obesity research.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.